Effect of delayed CNI-based immunosuppression with Advagraf® on liver function after MELD-based liver transplantation [IMUTECT]
Tóm tắt
MELD-based allocation for liver transplantation follows the “sickest-patient-first” strategy. The latter patients present with both, decreased immune competence and poor kidney function which is further impaired by immunosuppressants. In this prospective observational study, 50 patients with de novo low-dose standard Advagraf®-based immunosuppression consisting of Advagraf®, Mycophenolat-mofetil and Corticosteroids after liver transplantation will be evaluated. Advagraf® trough levels of 7-10 μg/l will be reached at the end of the first postoperative week. Immunostatus, infectious complications, graft and kidney function are compared between patients with a pretransplant calculated MELD-score of ≤20 and >20. Each group comprises of 25 consecutive patients. Prior to liver transplantation and on the postoperative days 1, 3 and 7, the patients’ graft function (LiMAx test) will be evaluated. On the postoperative days 3, 5 and 7 the patients’ immune status will be evaluated by the measurement of their monocytic HLA-DR status. Infectious complications (CMV-reactivation, wound infection, urinary tract infection, and pneumonia), graft- and kidney function will be analysed on day 0, within the first week, and 1, 3, 6, 9 and 12 months after liver transplantation. This study was designed to assess the effect of a standard low-dose Calcineurin inhibitor-based immunosuppression regime with Advagraf® on the rate of infectious complications, graft and renal function after liver transplantation. The trial is registered at “Clinical Trials” (
http://www.clinicaltrials.gov
), NCT01781195.
Tài liệu tham khảo
Gotthardt D, Weiss KH, Baumgärtner M, Zahn A, Stremmel W, Schmidt J, Bruckner T, Sauer P: Limitations of the MELD score in predicting mortality or need for removal from waiting list in patients awaiting liver transplantation. BMC Gastroenterol. 2009, 9: 72-10.1186/1471-230X-9-72.
Coombes JM, Trotter JF: Development of the allocation system for deceased donor liver transplantation. Clinical Med Res. 2005, 3 (2): 87-92. 10.3121/cmr.3.2.87.
Sawitzki B, Pascher A, Babel N, Reinke P, Volk HD: Can we use biomarkers and functional assays to implement personalized therapies in transplantation?. Transpl. 2009, 87 (11): 1595-1601. 10.1097/TP.0b013e3181a6b2cf.
Sawitzki B, Schlickeiser S, Reinke P, Volk HD: Pretransplant immune risk assessment. Curr Opin Organ Transpl. 2009, 14 (6): 650-655. 10.1097/MOT.0b013e32833281f8.
Sawitzki B, Schlickeiser S, Reinke P, Volk HD: Monitoring tolerance and rejection in organ transplant recipients. Biomarkers. 2011, 16 (Suppl 1): 42-50.
Döcke WD, Höflich C, Davis KA, Röttgers K, Meisel C, Kiefer P, Weber SU, Hedwig-Geissing M, Kreuzfelder E, Tschentscher P, Nebe T, Engel A, Monneret G, Spittler A, Schmolke K, Reincke P, Volk HD, Kunz D: Monitoring temporary immunodepression by flow cytometric measurement of monocytic HLA-DR expression: a multicenter standardized study. Clin Chem. 2005, 51 (12): 2341-2347. 10.1373/clinchem.2005.052639.
Haveman JW, van den Berg AP, van den Berk JM, Mesander G, Slooff MJ, de Leij LH, The TH: Low HLA-DR expression on peripheral blood monocytes predicts bacterial sepsis after liver transplantation: relation with prednisolone intake. Transpl Infect Dis. 1999, 1 (3): 146-152. 10.1034/j.1399-3062.1999.010302.x.
Perry SE, Mostafa SM, Wenstone R, Shenkin A, McLaughlin PJ: HLA-DR regulation and the influence of GM-CSF on transcription, surface expression and shedding. Int J Med Sci. 2004, 1 (3): 126-136.
van den Berk JM, Oldenburger RH, van den Berg AP, Klompmaker IJ, Mesander G, van Son WJ, van der Bij W, Sloof MJ, The TH: Low HLA-DR expression on monocytes as a prognostic marker for bacterial sepsis after liver transplantation. Transplantation. 1997, 63 (12): 1846-1848. 10.1097/00007890-199706270-00026.
Lock JF, Schwabauer E, Martus P, Videv N, Pratschke J, Malinowski M, Neuhaus P, Stockmann M: Early diagnosis of primary nonfunction and indication for reoperation after liver transplantation. Liver Transpl. 2010, 16 (2): 172-180. 10.1002/lt.21973.
Stockmann M, Lock JF, Riecke B, Heyne K, Martus P, Fricke M, Lehmann S, Niehues SM, Schwabe M, Lemke AJ, Neuhaus P: Prediction of postoperative outcome after hepatectomy with a new bedside test for maximal liver function capacity. Ann Surg. 2009, 250 (1): 119-125. 10.1097/SLA.0b013e3181ad85b5.
Jain AB, Venkataramanan R, Cadoff E, Fung JJ, Todo S, Krajack A, Starzl TE: Effect of hepatic dysfunction and T-tube clamping on FK 506 Pharmacokinetics and trough concentrations. Transpl Proc. 1990, 22 (1): 57-59.
Trotter JF, Olson J, Lefkowitz J, Smith AD, Arjal R, Kenison J: Changes in international normalized ratio (INR) and model for endstage liver disease (MELD) based on selection of clinical laboratory. Am J Transpl. 2007, 7 (6): 1624-1628. 10.1111/j.1600-6143.2007.01822.x.
Trotter JF, Brimhall B, Arjal R, Phillips C: Specific laboratory methodologies achieve higher model for endstage liver disease (MELD) scores for patients listed for liver transplantation. Liver Transpl. 2004, 10 (8): 995-1000. 10.1002/lt.20195.
Schnitzbauer AA, Doenecke A, Sothmann JL, Loss M, Farkas SA, Hartl J, Tsui TY, Baier L, Kirchner G, Obed A, Bein T, Geissler EK, Scherer MN, Schlitt HJ: Improved outcome after ‘Bottom-Up’ immunosuppression in liver transplant recipients with preoperative renal impairment. Eur Surg Res. 2010, 45: 356-367. 10.1159/000321702.
Lichtenstern C, Hochreiter M, Zehnter VD, Brenner T, Hofer S, Mieth M, Büchler MW, Martin E, Weigand MA, Schemmer P, Busch CJ: Pretransplant model for end stage liver disease score predicts posttransplant incidence of fungal infections after liver transplantation. Mycoses. 2013, 56 (3): 350-357. 10.1111/myc.12041.
Weismüller TJ, Negm A, Becker T, Barg-Hock H, Klempnauer J, Manns MP, Strassburg CP: The introduction of MELD-based organ allocation impacts 3-month survival after liver transplantation by influencing pretransplant patient characteristics. Transpl Int. 2009, 22 (10): 970-978. 10.1111/j.1432-2277.2009.00915.x.
Bruns H, Hillebrand N, Schneider T, Hinz U, Fischer L, Schmidt J, Goldschmidt AJ, Schemmer P: LabMELD-based organ allocation increases total costs of liver transplantation: a single-center experience. Clin Transpl. 2011, 25 (5): 558-565. 10.1111/j.1399-0012.2011.01483.x.
Paramesh AS, Roayaie S, Doan Y, Schwartz ME, Emre S, Fishbein T, Florman S, Gondolesi GE, Krieger N, Ames S, Bromberg JS, Akalin E: Post-liver transplant acute renal failure: factors predicting development of end-stage renal disease. Clin Transplant. 2004, 18: 94-99. 10.1046/j.1399-0012.2003.00132.x.
Sharma P, Welch K, Eikstadt R, Marrero JA, Fontana RJ, Lok AS: Renal outcomes after liver transplantation in the model for endstage liver disease era. Liver Transpl. 2009, 15: 1142-1148. 10.1002/lt.21821.
Neuberger JM, Memelok RD, Neuhaus P, Pirenne J, Samuel D, Isoniemi H, Rostaing L, Rimola A, Marshall S, Mayer AD, ReSpECT Study Group: Delayed introduction of reduced-dose tacrolimus, and renal function in liver transplantation: the ‘ReSpECT’ study. Am J Transpl. 2009, 9 (2): 327-336. 10.1111/j.1600-6143.2008.02493.x.
Wente MN, Sauer P, Mehrabi A, Weitz J, Büchler MW, Schmidt J, Schemmer P: Review of the clinical experience with a modified release form of tacrolimus [FK506E (MR4)]in transplantation. Clin Transpl. 2006, 20 (17): 80-84.
Trunečka P, Boillot O, Seehofer D, Pinna AD, Fischer L, Ericzon BG, Troisi RI, Baccarani U, Ortiz de Urbina J, Wall W, Tacrolimus Prolonged Release Liver Study Group: Once-daily prolonged-release tacrolimus (ADVAGRAF) versus twice.daily tacrolimus (PROGRAF) in liver transplantation. Am J Transpl. 2010, 10 (10): 2313-2323. 10.1111/j.1600-6143.2010.03255.x.
The pre-publication history for this paper can be accessed here:http://www.biomedcentral.com/1471-2482/14/64/prepub